Jun 30, 2023 8:00am EDT ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
Jun 29, 2023 8:00am EDT CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
May 15, 2023 5:00pm EDT ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 08, 2023 9:00am EDT ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
Apr 25, 2023 5:00pm EDT Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
Apr 24, 2023 7:30am EDT ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
Apr 10, 2023 7:30am EDT ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
Mar 29, 2023 8:30am EDT Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
Mar 13, 2023 9:00am EDT ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
Mar 13, 2023 7:00am EDT ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023